PT  - JOURNAL ARTICLE
AU  - Aminbakhsh, Ava P.
AU  - Théberge, Emilie T.
AU  - Burden, Elizabeth
AU  - Kalenga Adejumo, Cindy
AU  - Lehman, Anna
AU  - Sedlak, Tara L.
TI  - Exploring associations between estrogen and gene candidates identified by coronary artery disease genome-wide association studies
AID  - 10.1101/2024.08.29.24312812
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.29.24312812
4099  - http://medrxiv.org/content/early/2024/08/30/2024.08.29.24312812.short
4100  - http://medrxiv.org/content/early/2024/08/30/2024.08.29.24312812.full
AB  - Introduction Coronary artery disease (CAD) is the leading cause of death around the world, with well-described epidemiological sex and gender differences in prevalence, pathophysiology and management outcomes. It has been hypothesized that sex steroids, like estrogen, may contribute to these sex differences. There is a relatively large genetic component to developing CAD, with heritability estimates ranging between 40-60%. In the last two decades, the computational methods, capabilities and scalability of genome-wide association studies (GWAS) have contributed substantially to advancing the understanding of which genetic candidates contribute to CAD. The aim of this study was to determine if genes discovered in CAD GWASs are affected by estrogen by means of direct modulation or indirect down-stream targets.Methods A scoping review of the literature was conducted using MEDLINE and EMBASE through to April 24, 2024, for studies synonymous to an atherosclerotic coronary artery disease phenotype, and a genome-wide association study (GWAS) design. Analysis was limited to candidate genes with corresponding single nucleotide polymorphisms (SNPs) surpassing genome-wide significance and had been mapped to genes by study authors. The number of studies that conducted sex-stratified analyses with significant genes were quantified. A literature search of the final gene lists was done to examine any evidence suggesting estrogen may modulate the genes and/or gene products.Results There were 60 eligible CAD GWAS studies meeting inclusion criteria for data extraction. Of these 60, only 36 had genome-wide significant SNPs reported, and only 3 of these had significant SNPs from sex-stratified analyses mapped to genes. From these 36 studies, a total of 61 genes were curated, of which 26 genes (43%) were found to have modulation by estrogen. All 26 were discovered in studies that adjusted for sex. 12/26 genes were also discovered in studies that conducted sex-stratified analyses. 12/26 genes were classified as having a role in lipid synthesis, metabolism and/or lipoprotein mechanisms, while 11/26 were classified as having a role in vascular integrity, and 3/26 were classified as having a role in thrombosis.Discussion This study provides further evidence of the relationship between estrogen, genetic risk and the development of CAD. More sex-stratified research will need to be conducted to further characterize estrogen’s relation to sex differences in the pathology and progression of CAD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare no financial support was received for the publication of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript and supplemental material.